术后放化疗在无切缘阳性或包膜外侵犯的头颈部癌中的作用:倾向性评分匹配分析
该研究回顾性纳入2009年12月至2018年10月在本中心接受术后放化疗或术后放疗的无包膜外侵犯或切缘阳性的头颈部鳞状细胞癌患者,采用倾向性评分匹配分析。匹配后264例患者中,pN2-3和pT3-4为独立不良预后因素;总体两治疗组生存无显著差异,但pN2-3患者接受术后放化疗的3年总生存和局部区域无复发生存更优,pT3-4患者接受术后放化疗的3年局部区域无复发生存更高。
要点
- 匹配后264例无切缘阳性或包膜外侵犯的头颈部鳞癌患者纳入分析。
- pN2-3是总生存、无病生存、局部区域无复发生存和远处无转移生存的独立危险因素。
- pN2-3患者术后放化疗较术后放疗的3年总生存和局部区域无复发生存更优。
核心结论
- 在无切缘阳性或包膜外侵犯的头颈部鳞癌患者中,pN2-3和pT3-4是独立的不良预后因素,术后放化疗可改善pN2-3或pT3-4患者的生存结局。
研究设计与样本
- 回顾性纳入2009年12月至2018年10月在本中心接受术后放化疗或术后放疗的无包膜外侵犯或切缘阳性的头颈部鳞状细胞癌患者,采用倾向性评分匹配方法分析。
主要发现
- 匹配后共264例患者,其中pT3-4者142例(41.2%),pN2-3者136例(38.3%),神经周围侵犯者68例(21.1%),淋巴管/血管间隙侵犯者45例(12.8%)。
- 中位随访52个月,3年总生存、局部区域无复发生存、远处无转移生存和无病生存率分别为72.4%、79.3%、83.5%和62.5%。
- pN2-3是总生存(p < 0.001)、无病生存(p < 0.001)、局部区域无复发生存(p < 0.001)和远处无转移生存(p = 0.002)的独立危险因素,pT3-4是远处无转移生存的不良预后因素(p = 0.005)。
- 总体而言,术后放化疗组与术后放疗组在总生存(p = 0.062)、无病生存(p = 0.288)、局部区域无复发生存(p = 0.076)和远处无转移生存(p = 0.692)方面无显著差异。
- pN2-3患者接受术后放化疗较术后放疗的3年总生存更优(p = 0.050,63.9% vs. 47.9%),3年局部区域无复发生存也更优(p = 0.019,74.6% vs. 54.9%);pT3-4患者接受术后放化疗的3年局部区域无复发生存更高(p = 0.014,88.5% vs. 69.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this work was to determine whether patients with intermediate-risk head and neck squamous cell carcinoma (HNSCC) can benefit from postoperative chemoradiotherapy (POCRT). METHODS: Patients without extracapsular extension (ECE) or positive margins (PMs) who received POCRT or postoperative radiotherapy (PORT) at our center were retrospectively (December 2009 to October 2018) included for analysis, in particular, using a propensity score-matching method. RESULTS: After matching, 264 patients were enrolled, including 142 (41.2%) patients with pT3-4, 136 (38.3%) patients with pN2-3, 68 (21.1%) patients with perineural invasion, and 45 (12.8%) patients with lymphatic/vascular space invasion. With a median follow-up of 52 months, 3-year overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and disease-free survival (DFS) rates were 72.4%, 79.3%, 83.5% and 62.5%, respectively. pN2-3 was an independent risk factor for OS (p < 0.001), DFS (p < 0.001), LRFS (p < 0.001) and DMFS (p = 0.002), while pT3-4 was a poor prognostic factor for DMFS (p = 0.005). Overall, patients receiving POCRT had no significant differences from those receiving PORT in OS (p = 0.062), DFS (p = 0.288), LRFS (p = 0.076) or DMFS (p = 0.692). But notably, patients with pN2-3 achieved better outcomes from POCRT than PORT in 3-year OS (p = 0.050, 63.9% vs. 47.9%) and LRFS (p = 0.019, 74.6% vs. 54.9%). And patients with pT3-4 also had higher 3-year LRFS (p = 0.014, 88.5% vs. 69.1%) if receiving POCRT. CONCLUSIONS: Among all intermediate-risk pathological features, pN2-3 and pT3-4 were independent unfavorable prognostic factors for patients with HNSCC without PMs or ECE. POCRT can improve the survival outcomes of patients with pN2-3 or pT3-4.
引用
- Liu ZQ, OuYang PY, Zhang BY, et al. Role of postoperative chemoradiotherapy in head and neck cancer without positive margins or extracapsular extension: a propensity score-matching analysis. Radiat Oncol. 2022. PMID: 36372901. doi:10.1186/s13014-022-02152-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。